Loading…
← CockpitCompetitor Analysis › 300233.SZ Shandong Jincheng Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Shandong Jincheng Pharmaceutical Group Co., Ltd. Class A300233.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 30
Mkt cap
$604M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$12.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.2 pp
WACC 8.2%
Hurdle
+1 pp
Req g minus delivered
Close · CNYCN¥10.92
1D-1.7%
1W-6.3%
1M-12.4%
3M-23.1%
6M-31.3%
YTD-21.9%
1Y-37.5%
ATR %3.1%
52w lowhigh39.9% off high

What Shandong Jincheng Pharmaceutical does

Employees: 3,515

Shandong Jincheng Pharmaceutical at a glance

Size Shandong Jincheng Pharmaceutical (300233.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $604M, the 3227th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.92 on 18 Nov 2026.

Performance Over six months the shares fell 31.3%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +3.7%); the operating margin is 4.4% (peer median 4.1%).

Valuation It trades at 1.2× enterprise value to sales against a peer median of 3.5× (3rd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.2 points above its cost of capital (8.2% WACC).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 75300233.SZ 71
Six months, rebased to 100: Shandong Jincheng Pharmaceutical against the median of its 20 peers (local-currency closes).

Shandong Jincheng Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.83BCN¥2.72BCN¥3.35BCN¥3.52BCN¥3.49B
Revenue growth—-19%-5%+1%—
Gross profitCN¥1.14BCN¥850MCN¥1.21BCN¥1.43BCN¥1.50B
EBITDAn/aCN¥408MCN¥575MCN¥516MCN¥630M
Net incomeCN¥157MCN¥44.2MCN¥197MCN¥175MCN¥273M
Free cash flowCN¥316MCN¥220MCN¥154MCN¥323M-CN¥118M
Capital expenditureCN¥90.5MCN¥101MCN¥143MCN¥343MCN¥374M
Total debtCN¥365MCN¥533MCN¥658MCN¥820MCN¥849M

Quarterly statements and history in the cockpit →

Shandong Jincheng Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%DBV301096600976185750002793603567IMMX002940300194ORCHPHARMA4105300147OLMA301211CGEMBCAX6034392157300233.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Jincheng Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×30109660097618575000279360356730121121574743300233.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Jincheng Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%600976185750002793603567002940300194300147603439300233.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Jincheng Pharmaceutical is the large dot.

Shandong Jincheng Pharmaceutical competitors and peer comparison

How Shandong Jincheng Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Jincheng Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300233.SZPeer medianRank in peer set
1-month return-12.4%-11.8%9th lowest of 20
6-month return-31.3%-26.6%10th lowest of 20
Distance from 52-week high-39.9%-44.1%7th highest of 20
Revenue growth (TTM)+2.2%+3.7%7th lowest of 15
Operating margin4.4%4.1%6th highest of 14
EV / Sales1.2×3.5×3rd cheapest of 15
Growth the price implies (Req g, 7 yrs)-0.6%9.1%5th least demanding of 10
Growth delivered (Del g)-1.6%+2.1%5th lowest of 10
Hurdle (Req g minus delivered)+1.0 pp+8.1 pp5th least demanding of 10
ROIC minus cost of capital+0.2 pp-5.4 pp4th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a

Questions

Which companies are Shandong Jincheng Pharmaceutical's closest peers?
The cockpit's peer set: DBV Technologies (DBV.PA), Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), JIANMIN PHARMACEUTICAL (600976.SS), Chongkundang (185750.KS), Luoxin Pharmaceuticals Group Stock (002793.SZ), Achieve Life Sciences (QUIT), HeiLongJiang ZBD Pharmaceutical (603567.SS), Immix Biopharma (IMMX).
Is Shandong Jincheng Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.2× against a peer median of 3.5×, 3rd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shandong Jincheng Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -31.3% against -26.6% for the median peer; over one year -37.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.